We focus on new uses for existing therapies and technologies. This allows us to build on existing safety profiles and leverage known mechanisms of action. The result is accelerated development and a streamlined regulatory process.
Our most advanced product addresses an unmet need in dermatology and is currently in Phase 1b/2a testing in the U.S.
John Dobak, M.D., is the Chairman of 10xBio. He spent the last 20 years developing novel medical therapies and currently serves as the CEO of DermTech, the leader in genomics and precision medicine for dermatology. View profile on LinkedIn…
Dan Piacquadio, M.D., is a board member and leads the clinical and regulatory development for 10xBio. Dan has over 20 years experience in developing new medical therapies and currently serves as the CEO of Therapeutics, Inc. View profile on LinkedIn…
Get the most recent updates about 10xBio.
Recent Press Releases
10xBio Announces the Completion of Phase 1B Clinical Trial of 10XB101
SAN DIEGO (May 6, 2019) – 10xBio, LLC, a privately-held biotechnology company, announced today that it has completed a Phase 1B study of its novel injectable drug product for body contouring. The company’s drug product 10XB101 is a novel formulation of polidocanol which is approved in the U.S….
Recent Media Coverage
Xconomy: 10xBio Raises $2.7M to Test Body Sculpting Drug in Clinical Trial
Xconomy San Diego — John Dobak, a life sciences serial entrepreneur in San Diego, said a new startup he’s leading has raised $2.66 million to advance a drug that is already approved to shrink varicose veins through early-stage clinical trials testing it in a new use —fat reduction body sculpting.
Thank you for your interest in 10xBio. Complete the form below and we will get back to you soon.